Person: KIYICI, MURAT
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KIYICI
First Name
MURAT
Name
24 results
Search Results
Now showing 1 - 10 of 24
Publication Does liver transplant improve neurological symptoms in wilson disease? report of 24 cases(Başkent Üniversitresi, 2022-11-01) Aksoy, Fuat; Arslan, İbrahim Ethem; Özgür, Taner; Dündar, Halit Ziya; Çelik, Fatih; Demir, Aylin Bican; Özbek, Sevda Erer; Kıyıcı, Murat; Özkan, Tanju Başarır; Kaya, Ekrem; AKSOY, FUAT; Arslan, İbrahim Ethem; ÖZGÜR, TANER; DÜNDAR, HALİT ZİYA; ÇELİK, FATİH; BİCAN DEMİR, AYLİN; ERER ÖZBEK, ÇİĞDEM SEVDA; KIYICI, MURAT; Özkan, Tanju Başarır; KAYA, EKREM; Tıp Fakültesi; Organ Nakli Merkezi; 0000-0001-5808-9384; 0000-0002-9245-1241; 0000-0001-6739-8605; HII-8895-2022; ABD-3885-2020; AAG-7319-2021; FPE-9941-2022; EWI-3634-2022; JKN-9078-2023; KHB-9765-2024; DLN-1836-2022; FHW-0015-2022; JKL-3648-2023Objectives: Wilson disease is an inherited disorder that results in copper accumulation in the tissues with liver injury and failure. Orthotopic liver transplant is one of the treatments of choice for this disease. The aim of this study was to compare the neurological symptoms, before and after orthotopic liver transplant, of patients with liver cirrhosis due to Wilson disease, who represent a special group of patients with liver failure. Materials and Methods: Between 2007 and 2020, there were 24 patients with Wilson disease resistant to medical treatment who underwent deceased donor orthotopic liver transplant and were followed up for 1 year, 5 years, and 10 years for evaluation with neurological scoring systems. Patients were also evaluated for postoperative complications and survival. Results: Of the 24 patients evaluated, there were 13 (54.2%) female patients and 11 (45.8%) male patients, and the mean age was 34 years (range, 14-57 years). One of the patients died from early postoperative sepsis. After orthotopic liver transplant, disease scores returned to normal in 16 patients and improved in the remaining patients. Before transplant, all patients required help in their daily activities. After transplant, there were significant improvements in some symptoms, and the patients became more independent in their daily lives. Conclusions: Our study shows that orthotopic liver transplant provides significant improvement in neurological symptoms and quality of life in patients with Wilson disease.Publication Efficacy and safety of tenofovir alafenamide in hepatitis B virus-infected patients with chronic hemodialysis and renal transplantation: A preliminary result(Lippincott Williams & Wilkins, 2021-10-01) Adanır, Haydar; Etik, Diğdem Özer; Yıldırım, Abdullah Emre; Mehdiyev, Shahin; Yapalı, Suna; Coşar, Arif Mansur; Arı, Derya; Gökcan, Hale; Teker, Tufan; Kıyıcı, Murat; Balaban, Yasemin Hatice; Alkım, Hüseyin; Üçbilek, Enver; Ünsal, Yasemin; Harputluoğlu, Murat; Vatansever, Sezgin; Demir, Mehmet; Güzelbulut, Fatih; Gündüz, Feyza; Boyacıoğlu, Sedat; Bilgiç, Yılmaz; Ekmen, Nergis; Arslan, Mehmet; Şimşek, Halis; Akdoğan, Meral; Dinçer, Dinç; Tozun, Nurdan; İdilman, Ramazan; TEKER, TUFAN; KIYICI, MURAT; Tıp Fakültesi; Gastroenteroloji Ana Bilim Dalı; EAB-6931-2022; FHW-0015-2022Publication Risk factors and outcomes of the post-liver transplantation diabetes mellitus(Aves, 2022-09-01) Ünsal, Yasemin Aydoğan; Gül, Özen Öz; Göktuğ, Mehmet Refik; Cander, Soner; Ersoy, Canan Özyardımcı; Aydemir, Ensar; Ateş, Coşkun; Ünsal, Oktay; Kıyıcı, Murat; Ertürk, Erdinç; ÖZ GÜL, ÖZEN; GÖKTUĞ, MEHMET REFİK; CANDER, SONER; Ersoy, Canan Özyardımcı; AYDEMİR, ENSAR; ATEŞ, COŞKUN; KIYICI, MURAT; ERTÜRK, ERDİNÇ; Tıp Fakültesi; Dahiliye Ana Bilim Dalı; 0000-0001-8519-784X ; GBT-4320-2022; CSJ-5407-2022; CJH-1319-2022; JMT-8992-2023; AAB-6671-2022; CDO-0747-2022; FHW-0015-2022; AAJ-6536-2021Objective: We aimed to identify the risk factors for the development of diabetes mellitus after transplantation in liver recipients.Methods: Two hundred twenty-seven patients with a follow-up period >8 months after liver transplantation were included in the study. The clinical and laboratory data of patients with post-liver transplantation diabetes mellitus and without post-liver transplantation diabetes mellitus were compared.Results: Of the 227 patients, 61 patients were diagnosed with diabetes mellitus in the pretransplantation period. Twelve percent of the patients (20 patients) were diagnosed with post-liver transplantation diabetes mellitus and 146 patients were not diagnosed with diabetes mellitus. We found that post-liver transplantation diabetes mellitus was associated with advanced age (95% CI: 1.002-1.142). Male liver recipients were diagnosed with a higher rate of post-liver transplantation diabetes mellitus than female recipients (15.5% and 5.4%, respectively; P =.045). Pretransplantation fasting plasma glucose levels were higher in patients with post-liver transplantation diabetes mellitus than without post-liver transplantation diabetes mellitus, which was not statistically significant (P =.097). While 22.2% of patients with post-liver transplantation diabetes mellitus had complications after transplantation, 14.2% of the patients without post-liver transplantation diabetes mellitus had complications after transplantation (P =.370).Conclusion: As post-liver transplantation diabetes mellitus is associated with graft failure and increased mortality and morbididy, candidates for liver transplantation should be screened for risk factors of diabetes, and blood work for diabetes mellitus should be done regularly in these patients. Since patients with advanced age, male gender, and higher fasting plasma glucose levels in the pretransplantation period have higher risk for the development of post-liver transplantation diabetes mellitus, these cases should be screened more carefully.Publication Real life efficacy and tolerability of tenofovir alafenamide fumarate in patients with hepatitis B virus-related cirrhosis and liver transplant recipients. A-preliminary result(Wiley, 2021-10-01) Yapalı, Suna; Gökcan, Hale; Harputluoğlu, Murat; Ellik, Zeynep Melekoğlu; Akarsu, Mesut; Durak, Serdar; Gökçen, Pınar; Adanır, Haydar; Arı, Derya; Mehdiyev, Shahin; Vatansever, Sezgin; Güzelbulut, Fatih; Teker, Tufan; Alkım, Hüseyin; Bilgiç, Yılmaz; Arslan, Mehmet; Özdil, Kamil; Koç, Elif Sitre; Etik, Diğdem Özer; Yıldırım, Emre; Balaban, Yasemin Hatice; Gündüz, Feyza; Kıyıcı, Murat; Akdoğan, Meral; Boyacıoğlu, Sedat; Ekmen, Nergis; Tozun, Nurdan; Şimşek, Halis; Dinçer, Dinç; Idılman, Ramazan; TEKER, TUFAN; KIYICI, MURAT; Tıp Fakültesi; Gastroenteroloji Ana Bilim Dalı; EAB-6931-2022 ; FHW-0015-2022Publication Answer regarding comment on: Risk factors and outcomes of the post-liver transplantation diabetes mellitus(Aves, 2023-01-01) Ünsal, Yasemin Aydoğan; Gül, Özen Öz; Göktuğ, Mehmet Refik; Cander, Soner; Ersoy, Canan Özyardımcı; Aydemir, Ensar; Ateş, Coşkun; Ünsal, Oktay; Kıyıcı, Murat; Ertürk, Erdinç; ÖZ GÜL, ÖZEN; GÖKTUĞ, MEHMET REFİK; CANDER, SONER; ERSOY, CANAN; AYDEMİR, ENSAR; ATEŞ, COŞKUN; KIYICI, MURAT; ERTÜRK, ERDİNÇ; Tıp Fakültesi; Endokrinoloji ve Metabolizma Hastalıklar Ana Bilim Dalı; 0000-0001-8519-784X ; GBT-4320-2022; CSJ-5407-2022; CJH-1319-2022; JMT-8992-2023; AAB-6671-2022; CDO-0747-2022; FHW-0015-2022; AAJ-6536-2021Publication Mean platelet volume is an important predictor of hepatitis c but not hepatitis b liver damage(Wolters Kluwer Medknow Publications, 2015-09-01) Eminler, Ahmet Tarık; Uslan, Mustafa Ihsan; Ayyıldız, Talat; Irak, Kader; Kıyıcı, Murat; KIYICI, MURAT; Gürel, Selim; GÜREL, SELİM; Dolar, Enver; DOLAR, MAHMUT ENVER; Gülten, Macit; GÜLTEN, MACİT; Nak, Selim Giray; NAK, SELİM GİRAY; Tıp Fakültesi; Gastroenteroloji Ana Bilim Dalı; 0000-0002-0019-3207; 0000-0002-3208-6211; ABF-1568-2021; HLH-8209-2023; AAI-4213-2021; AAG-9177-2021Background: The mean platelet volume (MPV) is the most commonly used measure of platelet size and is a potential marker of platelet reactivity. In this study, we aimed to explore the relationship between hepatic histopathology in viral hepatitis and MPV levels, which are associated with platelet count and activity. Materials and Methods: We performed a retrospective case-control study of baseline histological and clinical parameters in chronic hepatitis B and C patients in our tertiary reference center between January 2005 and January 2011. Two hundred and five chronic hepatitis B patients and 133 chronic hepatitis C patients who underwent liver biopsy were included in the study. The patients were divided into two groups: Chronic hepatitis B and chronic hepatitis C and were additionally divided into groups of two according to histological activity index (HAI) and fibrosis scores obtained by liver biopsy results (according to the Ishak scoring system). The clinical characteristics of chronic viral hepatitis patients, including demographics, laboratory (especially MPV), and liver biopsy findings, were reviewed. Results: One hundred and forty-three patients were male (69.1%), and the mean age was 41.9 +/- 12.75 with an age range of 18-71 years in hepatitis B patients. In the classification made according to HAI, 181 patients were in the low activity group (88.3%) and 24 in the high activity group (11.7%). In the evaluation made according to fibrosis score, 169 patients were found to have early fibrosis (82.4%) and 36 were found to have advanced fibrosis (17.6%). In patients with hepatitis B, there was no statistically significant difference in terms of their MPV values between the two groups, separated according to their degree of activity and fibrosis. Sixty-three patients were male (47.3%), and the mean age was 50.03 +/- 12.75 with an age range of 19-75 years. In the classification made according to HAI, 109 patients were in low activity group (81.9%) and 24 in high activity group (18.1%). In the evaluation made according to fibrosis score, 101 patients were found to have early fibrosis (75.9%) and 32 have advanced fibrosis (24.1%). There was a statistically significant difference between the activity and fibrosis groups of the hepatitis C patients (P = 0.04 and P = 0.02, respectively). Conclusion: MPV values are more reliable in hepatitis C patients than hepatitis B for predicting the advanced damage in liver histology. This finding might be useful for the detection of early fibrosis and also starting early treatment, which is important in hepatitis C.Publication Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort(Wiley, 2019-06-01) İdilman, Ramazan; Demir, Mehmet; Aladağ, Murat; Erol, Cihan; Çavuş, Bilger; İliaz, Raim; Köklü, Hayrettin; Çakaloğlu, Yılmaz; Şahin, Memduh; Ersöz, Galip; Köksal, İftihar; Karasu, Zeki; Özgenel, Meriç; Turan, İlker; Gündüz, Feyza; Ataseven, Hüseyin; Akdoğan, Meral; Kıyıcı, Murat; Köksal, Aydın Şeref; Akhan, Sila; Günsar, Fülya; Tabak, Fehmi; Kaymakoglu, Sabahattin; Akarca, Ulus S.; Akarsu, Mesut; Alkim, Hüseyin; Araz, Filiz; Ateş, Fehmi; Aygen, Bilgehan; Balık, İsmail; Barut, Hüseyin S.; Baysal, Birol; Bolat, Aylin; Çelik, İlhami; Coşgun, Süleyman; Ensaroglu, Fatih; Gökcan, Hale; Gürel, Selim; Gürsoy, Şebnem; İnkaya, Ahmet Çağan; Kamilli, Cemil; Kav, Taylan; Kuruüzüm, Ziya; Önder, Fatih O.; Örmeci, Necati; Özbakır, Ömer; Özenirler, Seren; Özer, Birol; Özkan, Hasan; Poturoğlu, Şule; Senates, Ebubekir; Şimşek, Halis; Toka, Bilal; Ünal, Hakan; Yaras, Serkan; Yıldırım, Abdullah E.; Yıldırım, Beytullah; Yılmaz, Bülent; Yılmaz, Hasan; Yozgat, Ahmet; Yurdaydın, Cihan; Early Access Program EAP Study Grp; KIYICI, MURAT; Tıp Fakültesi; Gastroenteroloji Ana Bilim Dalı; 0000-0002-3208-6211; AAI-4213-2021The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma.Publication Trends and causes of etiology in adult liver transplant patients: Multicenter study(Elsevier, 2022-07-01) Akarsu, Mesut; Harputluoğlu, Murat; Yılmaz, Sezai; Gençdal, Genco; Akyıldız, Murat; Polat, Kamil Yalçın; Dinçer, Dinç; Adanır, Haydar; Turan, İlker; Günsar, Fulya; Karasu, Zeki; Gökcan, Hale; Karademir, Sedat; Kabacam, Gökhan; Kayhan, Meral Akdoğan; Kıyıcı, Murat; Gülşen, Murat Taner; Balaban, Hatice Yasemin; Doğrul, Ahmet Bülent; Dolu, Süleyman; Şenkaya, Ali; Ellik, Zeynep Melekoğlu; Eren, Fatih; İdilman, Ramazan; KIYICI, MURAT; EREN, FATİH; Tıp Fakültesi; Gastroenteroloji Bölümü; 0000-0003-2667-8963; FHW-0015-2022; JQJ-3328-2023Publication Blood-based biomarkers in Afp normal/stable hepatocellular carcinoma: Diagnostic and prognostic relevance of Mir-10b for patients on liver transplant list(Elsevier Science Inc, 2022-09-01) Aksoy, Fuat; Aksoy, Seçil Ak; Dündar, Halit Ziya; Tunca, Berrin; Erçelik, Melis; Tekin, Çağla; Kıyıcı, Murat; Selimoğlu, Kerem; Kaya, Ekrem; AKSOY, FUAT; Aksoy, Seçil Ak; DÜNDAR, HALİT ZİYA; TUNCA, BERRİN; Erçelik, Melis; Tekin, Çağla; KIYICI, MURAT; Selimoğlu, Kerem; KAYA, EKREM; İnegöl Meslek Yüksekokulu; Organ Nakli Merkezi; 0000-0001-5808-9384; 0000-0002-1619-6680; 0000-0003-3635-7282; 0000-0002-3760-9755; 0000-0002-9562-4195; HII-8895-2022; ADM-8457-2022; EWI-3634-2022; ABI-6078-2020; EUG-3329-2022; JIT-9986-2023; FHW-0015-2022; CDS-3299-2022; AAG-7319-2021Background. As a diagnostic criteria of hepatocellular carcinoma (HCC), the exact threshold of alpha-fetoprotein (AFP) is controversial. In additional, not all HCC tumors are AFP positive or secrete elevated amounts of AFP into the serum. However, the diagnosis of HCC is quite important on the liver transplant list. Therefore, the purpose of this study was to investigate the expression of circulating micro RNAs (miRNAs) in AFP-stable HCC patients. Thus, we aimed to determine a diagnostic biomarker in these patients.Methods. Sixteen miRNAs were evaluated using a real-time quantitative reverse transcription polymerase chain reaction system in AFP-stable HCC and AFP-trending HCC patients.Results. In our study, 46.7% (n = 28) of the patients diagnosed with HCC had stable/normal AFP levels. We detected that high expression of miR-24, miR-10b and the low expression of miR-143 were independently and significantly associated with HCC in AFP-stable compared with AFP trending (P <.05). Additionally, we demonstrated that the overexpression of miR-10b was associated with poor disease-free survival in HCC (P = 0.001).Conclusions. Although more clinical validations are needed for the diagnosis of HCC, our current results indicate that the coexistence of high expression of miR-10b and miR-24 may help clinicians adjust in the diagnosis of HCC in patients who are on the liver transplant list but awaiting biopsy for the diagnosis of HCC.Publication Tasl practice guidance on the clinical assessment and management of patients with nonalcoholic fatty liver disease(Kare Publ, 2023-01-01) Yılmaz, Yusuf; Zeybel, Müjdat; Adalı, Gupse; Coşar, Arif Mansur; Sertesen, Elif; Gökcan, Hale; Bahçecioğlu, Halil İbrahim; Şahin, Mustafa; Tulunay, Cansın; Ergün, İhsan; Turan, İlker; Idilman, Ilkay Sedakat; Çelikel, Çiğdem; Kırımlıoğlu, Hale; Akyol, Gülen; Yılmaz, Funda; Sökmensür, Cenk; Güveli, Hakan; Akarca, Ulus Salih; Aküz, Umit; Genç, Volkan; Akyıldız, Murat; Yazıhan, Nuray; Tutar, Engin; Ateş, Fehmi; Dinçer, Dinç; Balaban, Yasemin; Akdoğan, Meral; Sonsuz, Abdullah; Idilman, Ramazan; Kiyici, Murat; KIYICI, MURAT; Tıp Fakültesi; Gastroentoloji Ana Bilim Dalı; FHW-0015-2022Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease and is significantly associated with obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. NAFLD has become the most prevalent chronic liver disease in Western countries, and the proportion of NAFLD-related cirrhosis among patients on liver transplantation waiting lists has increased. In light of the accumulated data about NAFLD, and to provide a common approach with multi-disciplines dealing with the subject, it has become necessary to create new guidance for diagnosing and treating NAFLD. This guidance was prepared following an interdisciplinary study under the leadership of the Turkish Association for the Study of the Liver (TASL), Fatty Liver Special Interest Group. This new TASL Guidance is a practical application guide on NAFLD and was prepared to standardize the clinical approach to diagnosing and treating NAFLD patients. This guidance reflects many advances in the field of NAFLD. The proposals in this guidance are meant to aid decision-making in clinical practice. The guidance is primarily intended for gastroenterology, endocrinology, metabolism diseases, cardiology, internal medicine, pediatric specialists, and family medicine specialists.
- «
- 1 (current)
- 2
- 3
- »